Table 2.
Specification of analyses.
| Analysis # | Indication | Outcome | Source of [177Lu]Lu-DOTA-TATE data | Nature of [177Lu]Lu-DOTA-TATE data | Treatment arm | Source of comparator data | Nature of comparator data |
|---|---|---|---|---|---|---|---|
| 1 | P-NETs | OS | ERASMUS (P-NETs subgroup) | IPD | Everolimus | RADIANT-3 | KM |
| 2 | BSC | ||||||
| 3 | Sunitinib | NCT00428597 | |||||
| 4 | BSC | ||||||
| 5 | PFS | Everolimus | RADIANT-3 | ||||
| 6 | BSC | ||||||
| 7 | Sunitinib | NCT00428597 | |||||
| 8 | BSC | ||||||
| 9 | GI-NETs | PFS | ERASMUS (GI-NETs subgroup) | Everolimus | RADIANT-4 | ||
| 10 | BSC |
GI-NETs, gastrointestinal neuroendocrine tumours; P-NETs, pancreatic neuroendocrine tumours; OS, overall survival; PFS, progression-free survival; PLD, patient-level data; IPD, individual patient data; BSC, best supportive care; KM, Kaplan-Meier.